

Some genuine reasons for optimism

If yesterday I was quite scathing about the reasons for market optimism, today, I think they should be a bit more encouraged



Some genuine good news

Yesterday's vaccine-hope-based rally in risk assets had very feeble underpinnings. A very small-scale Covid-19 vaccine safety trial had managed to elicit an immune response, though with some fairly mixed side effects, and was clearly still some way off a vaccine that was proven, safe and could be produced on an industrial scale. The front runner all along in this vaccine race, The Oxford University trial, is looking much more promising, and you will be able to read all about it in your newswires and newspapers today. But suffice it to say that optimism is rising about the possibility of mass production of a vaccine, even as soon as this year. While that doesn't help us right now, it does offer grounds for optimism, and as such, I would think markets ought to be a bit more buoyant than they are, which suggests that recent gains were really running on fumes, rather than on solid fuel.

It is also positive from a risk asset perspective (leaving politics aside), that President Trump seems to be leaning against imposing sanctions on Chinese officials following his signature yesterday of the Hong Kong Autonomy Act. It may be that he is saving this up to use at a time that is more politically helpful as the Presidential Election nears. Whatever the reason, the absence of any imminent sanctions also bodes well for risk assets in the near term.

The spotlight seems to have shifted away from China to Russia in terms of geopolitical illumination, with Secretary of State, Mike Pompeo, making threats of sanctions over Nord Stream 2, and Turk Stream - two Russian gas pipelines that will supply gas to Europe and Turkey. Europe's counter to this, "Where are we supposed to get our gas from?", is not an unreasonable one. Though getting these gas pipelines up and running will clearly only address one aspect of Europe's energy security problem, and politically, will draw Turkey closer to Russia, and away from the West. That's probably what this is all about.

Busy day ahead

It's a busy day ahead with the China GDP and other activity data dump later this morning. We are struggling with the notion that China can virtually return to pre-Covid levels within one quarter, which is what the consensus figures are suggesting. Clearly, all is not back at 100% in China right now, and no one would reasonably expect it to be. So is this all an artefact of an implausible inventory build or something else? And if it is, shouldn't we be a bit concerned about the recovery's durability. Far too often, and especially in command economies, the focus is on GDP as an ultimate goal, when it is, in fact, quite a stupid goal. You can make GDP rise by some very counter-productive means and do plenty of damage to your economy and population in the attempt. There really are better targets. Still, we'll worry about the figure when it comes out. For what it is worth, we favour a much weaker number than the consensus growth numbers.

The Bank of Korea meets today, though they made it fairly clear at their last meeting that they were done easing. And with government stimulus money now flowing, and concern mounting again over Metropolitan Seoul house prices, the odds of a further easing from the BoK have lengthened considerably.

Australian labour market data due later this morning is centred on a 100K increase in jobs. I'd be tempted to suggest a stronger figure. Some of the most recently lost jobs will have been of the easy-come, easy-go variety and concentrated in the part-time sector. With the economy (outside Victoria) opening again, it is entirely conceivable that a lot of part-time jobs in retail and hospitality sectors will come back quite quickly. The harder work will be repairing damage to full-time employment, stemming from business failures during the Covid-19 crisis.

Outside of Asia, today's ECB meeting will probably be the main focus, though with little expected in terms of concrete policy measures. [Our economists and FX strategists write about what to expect in this note.](#)

And in the US, retail sales will continue to show strong gains but will remain well down on pre-Covid-19 levels, so the market can read these whichever way it wants depending on its prevailing mood.

Have a productive and safe day.

Author

Robert Carnell

Regional Head of Research, Asia-Pacific

robert.carnell@asia.ing.com

Disclaimer

This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. ("ING") solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. *ING forms part of ING Group (being for this purpose ING Group N.V. and its subsidiary and affiliated companies)*. The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.

The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.

Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.

Additional information is available on request. For more information about ING Group, please visit www.ing.com.